Mapping STING Mutations to Unlock Immunity and New Therapies

The innate immune system depends on molecular tripwires that detect when the careful compartmentalization of a healthy cell has failed. Among the most consequential of these sentinels is STING, the stimulator of interferon genes protein, an endoplasmic reticulum-resident adaptor that translates the presence of misplaced cytosolic DNA into a broad antiviral and antitumor transcriptional program. A newly published resource in Cell Research presents a systematic atlas of STING mutations, assembling into a single comparative framework the dozens of naturally occurring and experimentally characterized variants that have accumulated across human genetics, cancer genomics, and basic structural biology. By unifying these data, the atlas aims to do for STING biology what curated variant catalogs have done for other medically prominent proteins: convert scattered observations into a coherent map that connects molecular mechanism to clinical consequence.

The biological logic of STING makes such a map unusually valuable. Under normal conditions, STING resides in an inactive, self-inhibited conformation on the endoplasmic reticulum membrane, its ligand-binding domain held in a closed orientation. When cyclic dinucleotides, either bacterial second messengers or the mammalian cyclic GMP-AMP synthesized by the sensor cGAS after DNA leakage into the cytoplasm, bind to the ligand-binding pocket, STING rotates into an open state, exits the endoplasmic reticulum through the Golgi apparatus, and initiates a phosphorylation cascade through TBK1 and IRF3 that drives type I interferon and inflammatory cytokine production. The protein therefore operates as a conformational switch under tight negative control, and mutations that nudge the equilibrium in either direction produce distinctive disease phenotypes.

Gain-of-function variants of STING sit at one end of the clinical spectrum. Amino acid substitutions clustered in the dimerization interface and the lid region that covers the cyclic dinucleotide binding pocket destabilize the closed, inactive conformation, allowing spontaneous ligand-independent activation. Patients carrying such variants develop the autoinflammatory syndrome now classified as STING-associated vasculopathy with onset in infancy, or SAVI, characterized by systemic inflammation, interstitial lung disease, and vascular pathology that mirrors constitutive interferon signaling. Additional gain-of-function alleles have been linked to familial chilblain lupus and related interferonopathies, and mouse models carrying equivalent substitutions recapitulate the lethal inflammatory phenotype, confirming that the mutated protein itself, rather than an upstream sensing defect, drives pathology.

Loss-of-function variants occupy the opposite pole of the atlas. Biallelic inactivating mutations in the STING-encoding TMEM173 gene have been identified in patients presenting with a combined immunodeficiency marked by recurrent and severe viral infections, particularly respiratory viruses, alongside pulmonary disease. These alleles cluster in distinct structural neighborhoods: some disrupt ligand binding, others impair the conformational rearrangements needed for trafficking to the Golgi, and still others destabilize the protein so that steady-state abundance collapses. Intriguingly, a founder allele common in certain populations ablates STING function with apparently modest fitness cost, a reminder that evolutionary pressure from pathogens can shape the distribution of immune gene variants in ways that remain only partly understood.

Cancer adds a third interpretive layer to the mutation catalog. Tumors frequently acquire mutations that silence STING signaling, because intact STING activity, by recruiting and activating antigen-presenting cells within the tumor microenvironment, opposes immune evasion. Loss-of-function alterations of STING pathway components have been documented across a range of malignancies, including colorectal and gastric cancers, and correlate with diminished T-cell infiltration and poorer responses to immune checkpoint blockade. Conversely, pharmacological activation of STING with synthetic cyclic dinucleotide agonists has emerged as a major strategy in cancer immunotherapy, with numerous candidates advancing through preclinical and clinical evaluation. The atlas therefore serves a translational purpose: a clinician or drug developer can query whether a given tumor-associated substitution is predicted to ablate, enhance, or leave unaffected STING signaling, and can reason about how that functional assignment might inform immunotherapy selection.

What distinguishes a systematic atlas from a simple variant list is the integration of structural and biophysical annotation. High-resolution crystal and cryogenic electron microscopy structures of STING from human and multiple animal species have defined the ligand-binding pocket, the dimer interface, the hydrophobic lid, and the transmembrane segment, while molecular dynamics simulations have mapped the conformational transitions connecting inactive and active states. By projecting every cataloged missense mutation onto these structural ensembles, the resource makes mechanistic hypotheses explicit: substitutions can be classified by their proximity to the ligand pocket, their predicted effect on dimer stability, their likely influence on the trafficking sequence that shuttles STING from endoplasmic reticulum to Golgi, or their impact on the post-translational modification sites, including palmitoylation and phosphorylation, that modulate signaling intensity and duration.

The clinical translation dimension of the atlas extends beyond cancer. STING agonists are being explored as vaccine adjuvants and as treatments for chronic viral infections, where a transient burst of innate stimulation could strengthen adaptive immune responses. At the same time, excessive STING activation has been implicated in sterile inflammatory diseases, neurodegeneration, and aspects of aging biology, prompting the parallel development of STING inhibitors. An evidence-based map of how sequence variation alters STING function is directly relevant to both efforts, because it identifies which patient subgroups carry hypomorphic or hypermorphic alleles that could shift the therapeutic window. Precision dosing and patient stratification for STING-targeted drugs may ultimately depend on genotyping knowledge of exactly the kind this resource consolidates.

The methodological logic of atlas-building also deserves attention. Rather than relying on any single assay, the resource aggregates evidence from patient phenotypes, reporter assays measuring interferon promoter activation, protein localization studies, ligand-binding measurements, and animal models, assigning each variant a functional class supported by converging data. This convergence-based approach mitigates a chronic weakness of the field, in which individual studies using different cell lines and stimulation conditions have occasionally reported conflicting results for the same variant. By standardizing nomenclature, linking each entry to structural context, and flagging variants whose functional assignment rests on limited evidence, the atlas establishes a framework that future experimental work can extend systematically rather than idiosyncratically.

Several open questions frame the next phase of this effort. The functional consequences of many rare missense variants observed in large human sequencing cohorts remain untested, and the interplay between STING sequence variation and other innate immune genes, including cGAS itself and the downstream interferon receptor machinery, is only beginning to be explored. The pharmacological landscape is similarly incomplete: structural differences between human and rodent STING complicate the translation of agonists and inhibitors across species, and variants that alter drug binding pockets could produce patient-to-patient differences in treatment response. A living, continuously updated atlas offers a shared reference point for addressing these gaps, converting the accumulated knowledge of two decades of STING research into a practical instrument for genetic diagnosis, drug development, and, ultimately, the individualized treatment of the inflammatory, infectious, and malignant diseases in which this remarkable signaling protein sits at the center.

Subject of Research: Systematic functional and structural cataloging of STING protein mutations linked to autoinflammatory disease, immunodeficiency, and cancer immunotherapy

Article Title: Atlas-ing STING mutations to advance fundamental understanding and clinical translation

Article References: Zhang, B.-C., & Paludan, S. R. (2026). Atlas-ing STING mutations to advance fundamental understanding and clinical translation. Cell Research. https://doi.org/10.1038/s41422-026-01294-w

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01294-w

Keywords: STING, innate immunity, TMEM173, SAVI, interferon signaling, cGAS, cyclic dinucleotides, loss-of-function variants, gain-of-function variants, cancer immunotherapy, STING agonists, autoinflammatory disease